Совершенствование подходов к применению антагонистов кальция: фокус на лерканидипин

1. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5–26.
2. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213–25.
3. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64.
4. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356 (9227): 366–72.
5. Dahlof B, Sever P, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
6. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (28): 2417–28.
7. Girerd X, Hanon O, Pannier B et al. Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys. Ann Cardiol Angeiol (Paris), 2013. pii: S0003-3928(13)00061-9. doi: 10.1016/j.ancard.2013.04.011. [Epub ahead of print].
8. Dougall HT, McLay J. A comparative review of the adverse events of calcium antagonists. Drug Saf 1996; 15 (2): 91–106.
9. Ioulios P, Charalampos M, Effrosini P. The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopatogenetic mechanisms. Dermatol Online J 2003; 9 (5): 6.
10. Pruijm MT, Maillard MP, Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc Health Risk Manag 2008; 4 (6): 1159–66.
11. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003; 21 (5): 1003–10.
12. Romito R, Pansini MI, Perticone F et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5 (4): 249–53.
13. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study Group of the Regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14–21.
14. Leonetti G, Magnani B, Pessina AC et al. COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.
15. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano) 2000; 12 (5): 375–9.
16. Makarounas-Kirchmann K, Glover-Koudunas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercarnidipine and other dihydropiridine calcium channel blockers. Clin Ther 2009; 31 (2): 1652–63.
17. Millar-Craig M, Shaffu B, Greenough A et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17 (11): 799–806.
18. Barrios V, Navarro A, Esteras A et al. Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11 (2): 95–100.
19. Burnier M, Gasser UE. Efficacy and tolerability of lercarnidipine in patients with arterial hypertension: results of Phase IV study in general practice. Expert Opin Pharmacother 2007; 8 (14): 2215–23.
20. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2,5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998; 16 (12 Pt 1): 1831–8.
21. Barrios V, Escobar C, Navarro A et al. LAURA Investigators. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006; 60 (11): 1364–70.
22. Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.
23. Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48–56.
24. Martinez ML, Rizzi E, Castro MM et al. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008; 599 (1–3): 110–6.
25. Martinez ML, Lopes LF, Coelho EB et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006; 47 (1): 117–22.
26. Campo C, Saavedra J, Segura J et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med 2005; 96 (5): 365–71.
27. Robles NR, Pastor L, Manjón M et al. Lercanidipine in diabetic patients with renal failure. Nefrologia 2004; 24 (4): 338–43.
28. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.

В.В.Фомин*, С.В.Моисеев

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*dean-lech@yandex.ru

________________________________________________

V.V.Fomin*, S.V.Moiseev

I.M.Sechenov First Moscow State Medical University, Ministry of Health of Russia
*dean-lech@yandex.ru